Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Fast-Tracks Multiple HCV Drugs With Access In Mind

This article was originally published in PharmAsia News

Executive Summary

All eyes on a list of selected oral hepatitis C drugs that are expected to win out in China's notoriously lengthy approval battle, amid a potentially huge opening as Chinese HCV patients switch from interferon to all oral therapies.

Advertisement

Related Content

Sweeping China Policy Reforms Seen Bolstering Domestic Generics
VC Roundup: Infectious Disease Startup Snags $150m And Former Biogen CEO Scangos
2016 Review: Rapid Change Defines China Regulatory Environment
Gilead Taps New Talent In China Hepatitis Drug Access Drive
EU Group Wants Greater Reciprocity As Chinese Foreign Deals Expand

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel